Kwality Pharmaceuticals

What Kwality Pharmaceuticals does

Kwality Pharmaceuticals is an Indian generic pharmaceutical manufacturer headquartered in Amritsar, Punjab, founded in 1983. The company produces a broad portfolio that spans sterile injectables, oral solid dosages, cytotoxic/oncology products, beta-lactam antibiotics, cephalosporins, and—more recently—biologics (including the EPO biosimilar KWAI POIETIN) and complex depot formulations such as Goserelin Acetate Implant Injection. Its manufacturing base is organized across multiple dedicated units, with DSIR-recognized R&D enabling complex formulation work in microspheres and liposomes alongside conventional generics.

The company operates as a B2B generic manufacturer and exporter, selling into government tenders, institutional buyers, and distribution partners across more than 70 countries. Revenue is generated through product sales of formulations registered in multiple jurisdictions, with certifications including EU-GMP for Cephalosporin and Oncology units and DIGEMID approval in Peru. Its regulatory footprint in semi-regulated and emerging markets is the core of its commercial reach, while EU-GMP opens the door to regulated-market participation.

Financially, Kwality has delivered seven consecutive quarters of YoY revenue growth, with FY26 revenue of Rs 503.08 crore (approximately $60M USD) growing 35.89% YoY and net profit of Rs 67.35 crore growing 69% YoY. Q4 FY26 EBITDA margin expanded to 24.6% from 22%, with ROE of 16.91%, ROCE of 20.07%, and net debt-to-equity of 0.26x, indicating profitable growth funded largely through internal accruals. The company is BSE-listed following its 2022 migration to the Main Board, providing public-market access to capital for ongoing expansion.

Name

Kwality Pharmaceuticals

Legal name

Kwality Pharmaceuticals Limited

Website

https://kwalitypharma.com

Company type

Public

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kwality Pharmaceuticals is an Indian generic pharmaceutical manufacturer (founded 1983) producing injectables, oral solids, cephalosporins, oncology products, and biologics, exporting to 70+ countries through B2B distribution and government tenders.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIACAO

Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAJ

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Generic pharmaceutical manufacturing
• Complex injectables production
• Oncology drug manufacturing
• Cephalosporin antibiotics production
• Oral solid dosage forms

Headquarters

HQ city

Amritsar

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling generic pharmaceutical products across multiple therapeutic categories including oncology, anti-infectives, cardiovascular, CNS, and gastrointestinal medications. Products sold in 70+ international markets through regulatory approvals and partnerships.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Kwality Pharmaceuticals manufactures generic pharmaceutical products across multiple dosage forms and therapeutic categories at WHO-GMP, EU-GMP, and PIC/S certified facilities in Amritsar (Punjab) and Jassur (Himachal Pradesh). The portfolio spans generic liquid orals and injectables, oral solid dosage forms, oncology/cytotoxic drugs, beta-lactam antibiotics, cephalosporins, biologics, and complex injectables (microspheres, liposomes, ophthalmic suspensions), with a new Goserelin Acetate Implant Injection. The company also offers technology transfer services for international pharmaceutical facility setup.

Product overview

Kwality Pharmaceuticals Limited is a pharmaceutical manufacturer specializing in complex molecules using advanced technologies. The company operates a multi-facility manufacturing structure with Unit 1 in Amritsar (Generic, Injectable & OSD) and Unit 3 in Himachal Pradesh (Oncology, Injectable & OSD). The product portfolio encompasses Generic Liquid Orals & Injectables, Oral Solid Dosage (OSD) forms, Oncology/Cytotoxic products, Beta-Lactam antibiotics, Cephalosporin antibiotics, Biologics (including KWAI POIETIN), and complex injectables (microspheres, liposomes, ophthalmic suspensions). The company recently developed its first implant injection (Goserelin Acetate) and offers technology transfer services for international partners. Products are exported to over 60 countries worldwide including Europe, Asia, GCC, Africa, Russia, and CIS regions.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Liquid Orals and Injectables Generic liquid oral formulations and injectable products including ampoules, vials, and lyophilized products for general therapies, manufactured at the Amritsar facility established in 1983.
• Oral Solid Dosage (OSD) Products Oral solid dosage forms including tablets, capsules, and sachets manufactured for general therapies and beta-lactam products; capability added in 2007.
• Oncology / Cytotoxic Products Specialized cytotoxic drug products for cancer treatment manufactured at the Himachal Pradesh facility following EU standards, including injectable oncology drugs such as Carboplatin, Cytarabine, Docetaxel, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Imatinib, Irinotecan, Methotrexate, Oxaliplatin, Paclitaxel, Vinblastine, and Vincristine.
• Beta-Lactam Antibiotic Products Beta-lactam antibiotic products including Ampicillin, Cloxacillin, and related compounds manufactured in dedicated facilities.
• Cephalosporin Antibiotic Products Cephalosporin antibiotic products including Cefixime and Cephalexin, manufactured at dedicated facilities in Himachal Pradesh with WHO-GMP approval.
• Biologics (KWAI POIETIN) Biologic products including KWAI POIETIN, developed at the Biologics Unit established in 2023.
• Complex Injectables (Microspheres, Liposomes, Ophthalmic Suspensions) Niche complex injectable products including microspheres, liposomes, and ophthalmic suspensions developed through reverse engineering of off-patent drugs.
• Goserelin Acetate Implant Injection First implant injection product developed by Kwality Pharmaceuticals, representing entry into advanced drug delivery systems.
• Dermatology Products Topical dermatology products including Bacitracin ointment, Clotrimazole cream, Fusidic acid cream, Ketoconazole cream, Mometasone ointment, Mupirocin cream, Permethrin cream, and Tretinoin preparations.
• Cardiovascular Products Cardiovascular medications including Rosuvastatin tablets, Valsartan, and other cardiovascular drugs.
• CNS Products Central nervous system products including Carbamazepine, Biperiden, Risperidone, Fluphenazine, and other neurological and psychiatric medications.
• Technology Transfer Services Technology transfer cell services supporting the setting up of new pharmaceutical facilities for international partners, including transition from lab-scale to commercial manufacturing, formulation development, and document development.

Quantifiable outcome

• Seventh consecutive quarter of year-on-year revenue growth
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Intercontinental Pharma InccoreChannel Partner/ Reseller/ DistributorRegional partner representing Kwality Pharmaceuticals in Caribbean and LATAM markets. Led by Mr. Jani Shaikh, President and CEO.
• Mana PharmacoreChannel Partner/ Reseller/ DistributorRegional partner representing Kwality Pharmaceuticals in CIS, Africa, LATAM regions and EU markets. Led by Dr. Katayun Manavi, Founder.
• Medlife Medical SolutionscoreChannel Partner/ Reseller/ DistributorRegional partner representing Kwality Pharmaceuticals in Mexico market. Led by Mr. Sergio Jordan, Founder.
• S.D PharmacoreChannel Partner/ Reseller/ DistributorRegional partner representing Kwality Pharmaceuticals in MENA, GCC, and LATAM markets. Led by Mr. Deepak Bansal, Founder.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lupin Limited: Major Indian generic manufacturer with specialty, complex injectables, and biosimilars franchises across global markets. Comparable on therapeutic breadth and international regulatory footprint, though larger and more diversified.
• Ajanta Pharma: Indian specialty generic manufacturer with strong presence in emerging markets (Africa, Asia). Comparable geographic expansion strategy and emerging market focus, though with broader branded generics portfolio.
• Biocon Limited: Indian biopharmaceutical company with biologics, biosimilars, and complex injectables portfolios. Comparable on the biologics/specialty strategic direction Kwality is pursuing with KWAI POIETIN, though at much larger scale.
• Aurobindo Pharma: Large Indian generic manufacturer with broad portfolio across injectables, orals, and specialty including beta-lactams and cephalosporins. Comparable product overlap but operates at substantially larger scale and broader geography.

Direct peers

• Shilpa Medicare: Indian specialty generics manufacturer with strong oncology, complex injectables, and biologics/CDMO capabilities. Closely comparable to Kwality in therapeutic focus (oncology) and complex injectable manufacturing, though larger in scale.
• Gland Pharma: Pure-play injectable manufacturer with extensive US FDA, EU-GMP, and PIC/S approvals serving global markets. Most directly comparable on injectable manufacturing focus, though at meaningfully larger scale and US-centric.
• Natco Pharma: Indian pharma focused on oncology, complex generics, and specialty injectables with strong export orientation across emerging markets. Highly comparable in therapeutic mix and international regulatory strategy.
• Strides Pharma Science: Indian generic manufacturer with strong oral solid, injectable, and specialty franchises across emerging markets and regulated geographies. Comparable on multi-therapy portfolio and export-heavy model.
• Unichem Laboratories: Indian generic manufacturer with active pharmaceutical ingredients and finished dosage forms across multiple therapeutic categories including injectables. Similar mid-cap profile and export-oriented business model.

Others

• Hikal Limited: Indian CDMO and API manufacturer serving global pharma customers. Comparable as a manufacturing partner in the pharmaceutical supply chain, though focused on APIs rather than finished dosage forms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kwality-pharmaceuticals-pvt-ltd-

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kwality Pharmaceuticals